INVESTMENTS, PUBLIC OFFERINGS, INVESTOR RELATIONS, BRANDING AND MARKETING, AUTOMATIC PAYMENT PROCESSING
MARKET UPDATE:
Element Global (ELGL) moving forward on reverse merger, verifiable assets. It's time.
Borders Consulting Services is pleased to announce our agreement with Active Care (ACAR:otcbb). We believe the opportunity for significant gains exists based on the company's excellent management team and board of directors, superior product line, and most importantly, a well designed business plan, which their team is currently executing extremely well. The company recently completed a raise of $6 Million, which will propel revenue to record highs, both recurring and new revenue, and the expectation of profitability within the next two quarters. Please read more about Active Care in our "CLIENTS" section.
ALL YOU NEED TO KNOW ABOUT PRED
Expected launch 2018
•Approximately 7.5 million women suffer from endometriosis in the United States with only 2.5 million women currently diagnosed
•5 million women are estimated to suffer from endometriosis in the major international markets with 70 million women suffering globally
•Greater than $1Billion annual US market
•Tremendous need for new more effective/lower side-effect therapeutics to meet this unmet demand
•Suppresses the symptoms of endometriosis in women diagnosed with endometriosis
•Prevents the development of the disease
•Believed to be superior to all competitive pharmaceuticals currently on the market
•Combination of two or more existing FDA-approved compounds, whose safety has already been established over decades
•Coupled with EndoRisk® as a companion diagnostic NHP-07 can be given prior to development of endometriosis or becoming symptomatic to prevent the disease altogether
•Patent pending for combination of progesterone and NSAIDs (Non Steroidal Anti-Inflammatory Drugs)
•Patent pending to replace traditional NSAIDs with cannabinoids to reduce the long-term side effects of NSAIDs
Genetic diagnostics do not require approval by the FDA in order to go to market if the tests are Laboratory Developed Tests (“LDTs”), which are regulated under the Clinical Laboratory Improvement Amendments (“CLIA”). It is estimated that of the 2,000 genetic tests commercially available less than a dozen were reviewed by FDA. The American Clinical Laboratory Association (“ACLA”) filed a citizen petition on June 4, 2013 challenging the FDA’s authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act (FDCA). The ACLA stated, “CLIA allows laboratories the flexibility to develop and validate LDTs quickly to respond to public health needs.” The ACLA also wrote, “Laboratories are able to update LDTs regularly as medicine advances, so that patients have access to the most advanced testing.” LDTs are laboratory services, not products, and are not distributed, nor delivered or placed into market, noted the petition. “They are proprietary procedures for performing a diagnostic test using reagents and laboratory equipment, essentially know-how.”
•Approximately 7.5 million women suffer from endometriosis in the United States with only 2.5 million women currently diagnosed
•5 million women are estimated to suffer from endometriosis in the major international markets with 70 million women suffering globally
•Greater than $1Billion annual US market
•Tremendous need for new more effective/lower side-effect therapeutics to meet this unmet demand
•Suppresses the symptoms of endometriosis in women diagnosed with endometriosis
•Prevents the development of the disease
•Believed to be superior to all competitive pharmaceuticals currently on the market
•Combination of two or more existing FDA-approved compounds, whose safety has already been established over decades
•Coupled with EndoRisk® as a companion diagnostic NHP-07 can be given prior to development of endometriosis or becoming symptomatic to prevent the disease altogether
•Patent pending for combination of progesterone and NSAIDs (Non Steroidal Anti-Inflammatory Drugs)
•Patent pending to replace traditional NSAIDs with cannabinoids to reduce the long-term side effects of NSAIDs
Genetic diagnostics do not require approval by the FDA in order to go to market if the tests are Laboratory Developed Tests (“LDTs”), which are regulated under the Clinical Laboratory Improvement Amendments (“CLIA”). It is estimated that of the 2,000 genetic tests commercially available less than a dozen were reviewed by FDA. The American Clinical Laboratory Association (“ACLA”) filed a citizen petition on June 4, 2013 challenging the FDA’s authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act (FDCA). The ACLA stated, “CLIA allows laboratories the flexibility to develop and validate LDTs quickly to respond to public health needs.” The ACLA also wrote, “Laboratories are able to update LDTs regularly as medicine advances, so that patients have access to the most advanced testing.” LDTs are laboratory services, not products, and are not distributed, nor delivered or placed into market, noted the petition. “They are proprietary procedures for performing a diagnostic test using reagents and laboratory equipment, essentially know-how.”
Kenexa Corporation, turned to Borders starting at $12.50 per share! We communicated that the company was fundamentally worth in excess of $40 per share at the beginning of the campaign. Our retail brokers and investors bought KNXA from $11.50 per share all the way up to $33.00 per share. When IBM bought out Kenexa Corporation for $46 dollars a share, many of our regular investors were very impressed, and built wealth from our insight. Investor confidence is at an all time high, and we strive to identify similar success stories, but the only way to join in the success of these finds is to act.
Plug Power met resistance at $.78 per share for just shy of 2 years. A simple program by which our investors became aware of the fundamental strength and advances in technology, and several million shares later, the company recognized record volume and price appreciation almost instantaneously. The story was picked up by CNBC and other news agencies, and the rest is history.
